Short Interest of The Day: How Analysts Feel About TYME TECHNOLOGIES (OTCMKTS:TYMI) After Decrease in Sellers?

November 18, 2016 - By Adrian Mccoy   ·   0 Comments

Short Interest of The Day: How Analysts Feel About TYME TECHNOLOGIES (OTCMKTS:TYMI) After Decrease in Sellers?

The stock of TYME TECHNOLOGIES (OTCMKTS:TYMI) registered a decrease of 25.77% in short interest. TYMI’s total short interest was 7,200 shares in November as published by FINRA. Its down 25.77% from 9,700 shares, reported previously. With 3,100 shares average volume, it will take short sellers 2 days to cover their TYMI’s short positions. The stock last traded at $3.75 per share. It is down 53.07% since April 21, 2016 and is downtrending. It has underperformed by 57.50% the S&P500.

Tyme Technologies, Inc., formerly Global Group Enterprises Corp., conducts majority of its research and development activities and other business operations, through its subsidiary, Tyme Inc. . The company has a market cap of $397.73 million. Tyme is a clinical-stage biopharmaceutical company. It currently has negative earnings. Tyme is focused on the development and commercialization of highly targeted cancer therapeutics with a range of oncology indications.

TYMI Company Profile

Tyme Technologies, Inc., formerly Global Group Enterprises Corp., incorporated on August 22, 2014, conducts majority of its research and development activities and other business operations, through its subsidiary, Tyme Inc. (Tyme). Tyme is a clinical-stage biopharmaceutical company. Tyme is focused on the development and commercialization of highly targeted cancer therapeutics with a range of oncology indications. The Company’s another subsidiary, Luminant Biosciences, LLC, conducts the initial research and development of the Company’s therapeutic platform.

More notable recent Tyme Technologies Inc (OTCMKTS:TYMI) news were published by: Businesswire.com which released: “Tyme Technologies, Inc. Receives FDA Acceptance of Investigational New Drug …” on October 26, 2015, also Businesswire.com with their article: “Tyme Technologies, Inc. Reports Third Quarter 2015 Financial Results” published on November 23, 2015, Globenewswire.com published: “Tyme Technologies Begins Phase 1b/2 Clinical Trial for the Treatment of …” on June 13, 2016. More interesting news about Tyme Technologies Inc (OTCMKTS:TYMI) were released by: Businesswire.com and their article: “Tyme Technologies, Inc. Completes Reverse Merger” published on March 19, 2015 as well as Businesswire.com‘s news article titled: “Tyme Technologies, Inc. Submits Investigational New Drug Application for …” with publication date: September 30, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Adrian Mccoy


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>